Your browser doesn't support javascript.
A SARS-CoV-2 Neutralization Assay Using Single Molecule Arrays.
Gilboa, Tal; Cohen, Limor; Cheng, Chi-An; Lazarovits, Roey; Uwamanzu-Nna, Augusta; Han, Isaac; Griswold, Kettner; Barry, Nick; Thompson, David B; Kohman, Richie E; Woolley, Ann E; Karlson, Elizabeth W; Walt, David R.
  • Gilboa T; Harvard Medical School, Boston, MA, 02115, USA.
  • Cohen L; Brigham and Women's Hospital, Department of Pathology, Boston, MA, 02115, USA.
  • Cheng CA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
  • Lazarovits R; Harvard Medical School, Boston, MA, 02115, USA.
  • Uwamanzu-Nna A; Brigham and Women's Hospital, Department of Pathology, Boston, MA, 02115, USA.
  • Han I; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
  • Griswold K; Harvard Medical School, Boston, MA, 02115, USA.
  • Barry N; Brigham and Women's Hospital, Department of Pathology, Boston, MA, 02115, USA.
  • Thompson DB; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
  • Kohman RE; Harvard Medical School, Boston, MA, 02115, USA.
  • Woolley AE; Brigham and Women's Hospital, Department of Pathology, Boston, MA, 02115, USA.
  • Karlson EW; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
  • Walt DR; Harvard Medical School, Boston, MA, 02115, USA.
Angew Chem Int Ed Engl ; 60(49): 25966-25972, 2021 12 01.
Article in English | MEDLINE | ID: covidwho-1427057
ABSTRACT
Coronavirus disease 2019 (COVID-19) manifests with high clinical variability and warrants sensitive and specific assays to analyze immune responses in infected and vaccinated individuals. Using Single Molecule Arrays (Simoa), we developed an assay to assess antibody neutralization with high sensitivity and multiplexing capabilities based on antibody-mediated blockage of the ACE2-spike interaction. The assay does not require live viruses or cells and can be performed in a biosafety level 2 laboratory within two hours. We used this assay to assess neutralization and antibody levels in patients who died of COVID-19 and patients hospitalized for a short period of time and show that neutralization and antibody levels increase over time. We also adapted the assay for SARS-CoV-2 variants and measured neutralization capacity in pre-pandemic healthy, COVID-19 infected, and vaccinated individuals. This assay is highly adaptable for clinical applications, such as vaccine development and epidemiological studies.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Neutralization Tests / Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Angew Chem Int Ed Engl Year: 2021 Document Type: Article Affiliation country: Anie.202110702

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Neutralization Tests / Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Angew Chem Int Ed Engl Year: 2021 Document Type: Article Affiliation country: Anie.202110702